Heparin-binding epidermal growth factor-like growth factor binding proteins

US8828382B2 · kind B2 · utility

Assignees

• U3 Pharma GmbH · DE
• AMGEN INC. · US

Inventors

• Mike Rothe · San Mateo, US
• Norbert Prenzel · Krailling, DE
• Eric Borges · Weitensfeld im Gurktal, AT
• Thore Hettmann · Birkenfeld, DE
• Esther Zwick-Wallasch · Birkenfeld, DE
• Orit Foord · Foster City, US

Key dates

• Filing date: Sep 26, 2008
• Grant date: Sep 9, 2014
• Expiry date: Mar 20, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (HB-EGF) and neutralize the biological functions of this growth factor.